2016, Number 11
PDF size: 509.51 Kb.
ABSTRACTObjetive: The main objective of this task consists on reviewing the existing literature in which the possible benefits of the antithrombotic therapy are studied in the prevention of complications caused by the placenta in order to acquire an acceptable clinical training and in order to suggest different areas of study related to this topic in a future.
Material and Method: In order to carry out this revision, a search of several studies published by Pubmed has been done. Clinical trials controlled in which it has been compared the possible benefit of the antithrombotic prenatal therapy opposite to the expectant conduct, in women with obstetric unfavorable precedents, with the aim to evaluate the prevention of complications caused by the placenta. In this revision, articles in which the effects of the heparin in techniques of assisted reproduction, abortions of repetition in the first trimester, antiphospholipid antibodies and thromboembolic venous diseases have not been included.
Results: After our research, 8 articles have been chosen with a total sample of 1178 women. Our revision shows a significant statistically reduction in the recurrence of hypertensive states of pregnancy (EHE), serious pre-eclampsia and minor for the gestational age (PEG) in those women who receive treatment with heparin during the pregnancy oppose to others who did not receive.
Conclusion: In spite of the fact that there seems to exist a decrease of recurrence of complications caused by the placenta such as EHE and PEG with the use of heparin, it is important to explain that in every clinical test included in our review, both the obstetric precedents, and the intervention, as well as the evaluated results are far between them for what the interpretation of the results must be done warily.
Kujovich JL. Thrombophilia and pregnancy complications. American Journal of Obstetrics and Gynecology. 2004; 191: 414-424
ACOG Committee on Practice Bulletins. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Obstetrics and Gynecology. 2002; 77: 67-75
Servicio de Medicina Maternofetal, Instituto Clínico de Ginecología, Obstetricia y Neonatología, Hospital Clínico de Barcelona. Hipertensión y gestación. Disponible en: https://medicinafetalbarcelona.org/clinica/images/protocolos/ patologia_materna_obstetrica/hipertensi%F3n%20 y%20gestaci%F3n.pdf. Actualizado en 2013
Huppertz, B. Placental pathology in pregnancy complications. Thrombosis Research. 2011; 127, S96-S99
Elizalde-Valdés VM, Calderón-Maldonado AE, García Rillo-A, Díaz Flores M. Abruptio placentae: morbimortalidad y resultados perinatales. Medicina e Investigación 2015;3(2):109-115
Luckas M. Fetal growth restriction in Obstetrics and Gynecology. An evidence-based text for MRCOG. Luesley DM, Baker PN (eds). Arnold (Publ). London 2004; p. 245-52
Lausman A, Kingdom J, Gagnon R, Basso M, Bos H, Crane J, Davies G, Delisle MF, Hudon L, Menticoglou S, Mundle W, Ouellet A, Pressey T, Pylypjuk C, Roggensack A, Sanderson F. Intrauterine growth restriction: sreeening, diagnosis, and management. Journal of Obstetrics and Gynaecology Canada. 2013; 35, 741-757
Christiansen DM, Elklit A, Olff M. Parents bereaved by infant death: PTSD symptoms up to 18 years after the loss. General Hospital Psychiatry.2013; 35, 605-611
Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, Walker LD, Greaves M, Brenkel I, Regan L, Greer IA. Thrombophilia in pregnancy: a systematic review. British Journal of Haemology. 2006; 132, 1271-196
Rodger MA, Betancourt MT, Clark P, Lindqvist PG, Dizon- Townson D, Said J, Seligsohn U, Carrier M, Salomon O, Greer IA. The associatrion of factor V leiden and prothrombin gene mutation and placetna-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. PloS Medicine. 2010; 7, e1000292
Van Rijn BB, Hoeks LB, Bots ML, Franx A, Bruinse HW. Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia. American Journal of Obstetrics and Gynecology. 2006;195(3):723-728
Rodger MA, Walker MC, Smith GN, Wells PS, Ramsay T, Langlois NJ, Carson N, Carrier M, Rennicks WR, Shachkina S, Wen SW. Is thrombophilia associated with placentamediated pregnancy complications? A prospective cohort study. Journal of Thrombosis and Haemostasis, 2014. 12, 469-478
Florez J. Armijo JA, Mediavilla A. Farmacología de la hemostasia, la coagulación y la fibrinolisis. Farmacología humana. 5th ed. Elsevier; 2008. p. 899-903
D´Ippolito S, Ortiz AS, Veglia M, Tersigni C, Di SN. Low molecular weight heparin in obstetric care: a review of the literature. Reproductive Sciences. 2011, 18, 602-613
Greer IA, Brenner B, Gris JC. Antithrombotic treatment for pregnancy complications: which path for the journey to precision medicine? British Journal of Haematology. 2014. 165, 585-599.
Kingdom JC, Drewlo S. Is heparin a placental anticoagulant in high-risk pregnancies. Blood. 2011. 118, 4780-4788
Urrútia G, Bonfill X. Declaración Prisma: Una propuesta para mejorar la publicación de revisiones sistemáticas y metaanálisis. Medicina Clínica. 2010. 135(11), 507-511. http://www.elsevier.es/es-revista-medicina-clinica-2-articulo- declaracion prisma-una-propuesta-mejorar-S0025 775310001454?redirectNew=true
Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2008. Disponible en www.cochranehandbook. org
Mello G, Parretti E, Fatini C, Riviello C, Gensini F, Marchionni M, Scarselli GF, Gensini GF, Abbate R. Low molecular weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensinconverting enzyme DD women. Hypertension. 2005. 45, 86-91
Rey E, Garneau P, David M, Gauthier R, Leduc L, Michon N, Mortin F, Demers C, Kahn SR, Magee LA, Rodger M. Dalteparin for the prevention of recurrence of placental mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. Journal of Thrombosis and Haemostasis. 2009. 7, 58-64
Gris JC, Chauleur C, Faillie JL, Baer G, Mares P, Fabbro-Peray P, Quere I, Lefrant JY, Haddad B, Dauzat M. Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial. Thombosis and Haemostasis. 2010. 104, 771-779
Gris JC, Chauleur, C, Molinari N, Mares P, Fabbro-Peray P, Quere I, Lefrant JY, Haddad B, Dauzat M. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial. Thrombosis and Haemostasis. 2011. 106, 1053-1061
Martinelli I, Ruggenenti P, Cetin I, Pardi G, Perna A, Vergani P, Acaia B, Facchinetti F, La Sala GB, Bozzo M, Rampello S, Marozio L, Diadei O, Gherardi G, Carminati S, Remuzzi G, Mannucci PM. Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood. 2012. 119, 3269-3275
Rodger MA, Hague WM, Kingdom J, Kahn SR, Karovitch A, Sermer M, Clement AM, Coat S, Chan WS, Said F, Rey E, Robinson S, Khurana R, Demers C, Kovacs MJ, Solymoss S, Hinshaw K, Dwyer J, Smith G, McDonald S, Newstead- Angel J, McLeod A, Khandelwal M, Silver RM, Le Gal G, Greer IA, Keely E, Rosene-Montella K, Walker M, Wells PS; TIPPS Investigators. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with trombophilia (TIPPS): a multinational open-label randomised trial. The Lancet. 2014. 384(9955): 1673-1683
de Vries JI, van Pampus MG, Hague WM, Bezemer PD, Joosten JH; FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Thrombosis and Haemostasis. 2012. 10(1): 64-72
Kim M, Hayashi RH, Gambone JC. Obstetric Hemorrhage and Puerperal Sepsis. Abruptio Placentae. Essencial of Obstetrics and Gynecology. 5th ed. Philadelphia: Saunders- Elsevier; 2010. p. 130-131
Hernández JM, Puente JM. Muerte fetal anteparto sin causa. Tratado de Ginecología, Obstericia y Medicina de la Reproducción. Cabero L (ed). Madrid: Ed. Panamericana. 2003. p 959-966.